questionsmedicales.fr
Phénomènes physiologiques
Phénomènes pharmacologiques et toxicologiques
Pharmacocinétique
Équivalence thérapeutique
Équivalence thérapeutique : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Équivalence thérapeutique : Questions médicales les plus fréquentes",
"headline": "Équivalence thérapeutique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Équivalence thérapeutique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-04",
"dateModified": "2025-03-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Équivalence thérapeutique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pharmacocinétique",
"url": "https://questionsmedicales.fr/mesh/D010599",
"about": {
"@type": "MedicalCondition",
"name": "Pharmacocinétique",
"code": {
"@type": "MedicalCode",
"code": "D010599",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G07.690.725"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Équivalence thérapeutique",
"alternateName": "Therapeutic Equivalency",
"code": {
"@type": "MedicalCode",
"code": "D013810",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sean M Hays",
"url": "https://questionsmedicales.fr/author/Sean%20M%20Hays",
"affiliation": {
"@type": "Organization",
"name": "Summit Toxicology, LLC, Bozeman, MT, USA. Electronic address: shays@summittoxicology.com."
}
},
{
"@type": "Person",
"name": "Erik Arntzen",
"url": "https://questionsmedicales.fr/author/Erik%20Arntzen",
"affiliation": {
"@type": "Organization",
"name": "Department of Behavioral Science, Oslo Metropolitan University, Oslo 0167, Norway erik.arntzen@equivalence.net."
}
},
{
"@type": "Person",
"name": "Christopher R Kirman",
"url": "https://questionsmedicales.fr/author/Christopher%20R%20Kirman",
"affiliation": {
"@type": "Organization",
"name": "Summit Toxicology, LLC, Bozeman, MT, USA."
}
},
{
"@type": "Person",
"name": "Sanjay Kalra",
"url": "https://questionsmedicales.fr/author/Sanjay%20Kalra",
"affiliation": {
"@type": "Organization",
"name": "Department of Endocrinology, Bharti Hospital, Karnal, India."
}
},
{
"@type": "Person",
"name": "Laxmaiah Manchikanti",
"url": "https://questionsmedicales.fr/author/Laxmaiah%20Manchikanti",
"affiliation": {
"@type": "Organization",
"name": "Pain Management Centers of America, Paducah, KY and Evansville, IN"
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Long noncoding RNA LIRIL2R modulates FOXP3 levels and suppressive function of human CD4",
"datePublished": "2024-05-28",
"url": "https://questionsmedicales.fr/article/38805281",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1073/pnas.2315363121"
}
},
{
"@type": "ScholarlyArticle",
"name": "Silc1 long noncoding RNA is an immediate-early gene promoting efficient memory formation.",
"datePublished": "2023-09-23",
"url": "https://questionsmedicales.fr/article/37742186",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.celrep.2023.113168"
}
},
{
"@type": "ScholarlyArticle",
"name": "Potential serum metabolites and long-chain noncoding RNA biomarkers for endometrial cancer tissue.",
"datePublished": "2022-12-12",
"url": "https://questionsmedicales.fr/article/36510632",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jog.15494"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long noncoding RNA",
"datePublished": "2024-02-26",
"url": "https://questionsmedicales.fr/article/38481861",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/tau-23-624"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long noncoding RNA ARTA controls ABA response through MYB7 nuclear trafficking in Arabidopsis.",
"datePublished": "2023-06-07",
"url": "https://questionsmedicales.fr/article/37290444",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.devcel.2023.05.003"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques",
"item": "https://questionsmedicales.fr/mesh/D010829"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes pharmacologiques et toxicologiques",
"item": "https://questionsmedicales.fr/mesh/D002620"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pharmacocinétique",
"item": "https://questionsmedicales.fr/mesh/D010599"
},
{
"@type": "ListItem",
"position": 5,
"name": "Équivalence thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013810"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Équivalence thérapeutique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Équivalence thérapeutique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Équivalence thérapeutique",
"description": "Comment évaluer l'équivalence thérapeutique ?\nQuels tests sont utilisés pour l'équivalence ?\nQuelles sont les normes d'évaluation ?\nQui réalise les évaluations d'équivalence ?\nQuels sont les critères d'inclusion ?",
"url": "https://questionsmedicales.fr/mesh/D013810?mesh_terms=RNA,+Long+Noncoding&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Équivalence thérapeutique",
"description": "Quels symptômes indiquent une non-équivalence ?\nComment reconnaître une réaction allergique ?\nQuels signes d'inefficacité observer ?\nLes symptômes varient-ils selon les traitements ?\nQuels symptômes nécessitent un avis médical ?",
"url": "https://questionsmedicales.fr/mesh/D013810?mesh_terms=RNA,+Long+Noncoding&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Équivalence thérapeutique",
"description": "Comment prévenir les erreurs de traitement ?\nQuelles sont les bonnes pratiques de prescription ?\nComment informer les patients sur l'équivalence ?\nQuels outils aident à la prévention des erreurs ?\nPourquoi est-il important de connaître l'équivalence ?",
"url": "https://questionsmedicales.fr/mesh/D013810?mesh_terms=RNA,+Long+Noncoding&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Équivalence thérapeutique",
"description": "Quels traitements sont souvent équivalents ?\nComment choisir entre deux traitements équivalents ?\nLes traitements équivalents ont-ils les mêmes effets ?\nComment évaluer la sécurité des traitements ?\nLes traitements équivalents nécessitent-ils des doses différentes ?",
"url": "https://questionsmedicales.fr/mesh/D013810?mesh_terms=RNA,+Long+Noncoding&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Équivalence thérapeutique",
"description": "Quelles complications peuvent survenir avec des traitements équivalents ?\nComment gérer les complications liées aux traitements ?\nLes complications sont-elles prévisibles ?\nQuels sont les signes d'une complication grave ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D013810?mesh_terms=RNA,+Long+Noncoding&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Équivalence thérapeutique",
"description": "Quels facteurs augmentent le risque d'échec thérapeutique ?\nComment l'adhérence au traitement affecte-t-elle l'équivalence ?\nLes antécédents médicaux influencent-ils l'équivalence ?\nQuels facteurs environnementaux jouent un rôle ?\nComment évaluer les facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D013810?mesh_terms=RNA,+Long+Noncoding&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'équivalence thérapeutique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des études cliniques comparatives et des méta-analyses."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour l'équivalence ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de bioéquivalence et des études de pharmacocinétique sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quelles sont les normes d'évaluation ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les normes incluent des critères de sécurité, d'efficacité et de qualité des médicaments."
}
},
{
"@type": "Question",
"name": "Qui réalise les évaluations d'équivalence ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les agences de régulation, comme l'ANSM, et des chercheurs indépendants effectuent ces évaluations."
}
},
{
"@type": "Question",
"name": "Quels sont les critères d'inclusion ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la population cible, les indications et les méthodes de traitement."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une non-équivalence ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets indésirables ou une efficacité réduite peuvent signaler une non-équivalence."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent éruption cutanée, démangeaisons, et gonflement après administration."
}
},
{
"@type": "Question",
"name": "Quels signes d'inefficacité observer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'absence d'amélioration des symptômes après un traitement peut indiquer une inefficacité."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les traitements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent provoquer des symptômes différents selon leur composition."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un avis médical ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves ou persistants après un traitement doivent être évalués par un médecin."
}
},
{
"@type": "Question",
"name": "Comment prévenir les erreurs de traitement ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vérification des prescriptions et l'éducation des patients sont essentielles."
}
},
{
"@type": "Question",
"name": "Quelles sont les bonnes pratiques de prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des protocoles standardisés et vérifier les allergies des patients."
}
},
{
"@type": "Question",
"name": "Comment informer les patients sur l'équivalence ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournir des brochures et des consultations pour expliquer les options de traitement."
}
},
{
"@type": "Question",
"name": "Quels outils aident à la prévention des erreurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des logiciels de gestion des prescriptions et des alertes de sécurité peuvent aider."
}
},
{
"@type": "Question",
"name": "Pourquoi est-il important de connaître l'équivalence ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela permet de choisir le traitement le plus approprié et de réduire les coûts."
}
},
{
"@type": "Question",
"name": "Quels traitements sont souvent équivalents ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les génériques et les médicaments de marque pour la même indication sont souvent équivalents."
}
},
{
"@type": "Question",
"name": "Comment choisir entre deux traitements équivalents ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix dépend de la tolérance, du coût et des préférences du patient."
}
},
{
"@type": "Question",
"name": "Les traitements équivalents ont-ils les mêmes effets ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils doivent avoir des effets cliniques similaires, mais peuvent différer en effets secondaires."
}
},
{
"@type": "Question",
"name": "Comment évaluer la sécurité des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La sécurité est évaluée par des études cliniques et des rapports d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les traitements équivalents nécessitent-ils des doses différentes ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas nécessairement, mais des ajustements peuvent être nécessaires selon le patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des traitements équivalents ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des réactions allergiques ou des interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux traitements ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial d'arrêter le traitement et de consulter un professionnel de santé."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles, surtout avec des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes tels que des douleurs thoraciques ou des difficultés respiratoires sont alarmants."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et une communication ouverte avec le médecin sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'échec thérapeutique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge, les comorbidités et l'adhérence au traitement influencent le risque."
}
},
{
"@type": "Question",
"name": "Comment l'adhérence au traitement affecte-t-elle l'équivalence ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une mauvaise adhérence peut réduire l'efficacité, rendant l'équivalence difficile à évaluer."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils l'équivalence ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de réactions aux médicaments peuvent affecter le choix du traitement."
}
},
{
"@type": "Question",
"name": "Quels facteurs environnementaux jouent un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'alimentation, le mode de vie et l'exposition à des toxines peuvent influencer."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation complète de l'historique médical et des habitudes de vie est nécessaire."
}
}
]
}
]
}
Regulatory T cells (Tregs) are central in controlling immune responses, and dysregulation of their function can lead to autoimmune disorders or cancer. Despite extensive studies on Tregs, the basis of...
Long noncoding RNAs (lncRNAs) are expressed in many brain circuits and types of neurons; nevertheless, their functional significance for normal brain functions remains elusive. Here, we study the func...
Endometrial carcinoma (EC) is one of the most common tumors in the female reproductive system. There are nearly 200 000 new cases every year. It is the third most common gynecological malignant tumor ...
The potential metabolic markers of endometrial cancer were screened by liquid chromatograph mass spectrometer (LC-MS), and the tissues of patients with hysteromyoma and endometrial cancer were sequenc...
Serum and tissue samples were collected from patients with endometrial dysplasia, endometrial cancer stage I, and endometrial cancer stage III. The metabolites in all serum samples were extracted, and...
Through synthesis of T test, cluster heatmap, and ROC curve analysis, five biomarkers with potential diagnostic ability were obtained, including 2,3-Pyridinedicarboxylic acid (area under the curve (AU...
It can combine the results of metabolomics and lncRNA sequencing to assist in the early diagnosis of endometrial precancerous lesions and endometrial cancer patients, to enhance the sensitivity and sp...
Clear cell renal cell carcinoma (RCC) is the most common subtype of RCC. Although targeted therapy can provide superior treatment outcomes, it is prone to drug resistance, and individual responses to ...
Small interfering RNA (siRNA) and plasmid cloning DNA (pcDNA) 3.1 were used to transfect renal cancer cell line 786-0 to silence and overexpress the lncRNA...
Compared with blank control group and negative control group, the siGPRC5D-AS1 group showed a significant decrease in the relative expression of lncRNA...
Silencing the expression of lncRNA...
In eukaryotes, transcription factors are a crucial element in the regulation of gene expression, and nuclear translocation is the key to the function of transcription factors. Here, we show that the l...
Gastric carcinoma high expressed transcript 1 (GHET1) is an oncogenic Long noncoding RNA. GHET1 expression promotes multiple levels of developing a complex molecular network. The main purpose of the s...
The widely accepted explanation of preeclampsia (PE) pathogenesis is insufficient trophoblast invasion and impaired uterine spiral artery remodeling. However, the underlying molecular mechanism remain...
We performed transcriptome sequencing on placentas of normal and PE patients and identified 976 differentially expressed long noncoding RNAs (lncRNAs). TCF21 antisense RNA inducing demethylation (TARI...
We concluded that the downregulation of TARID expression may inhibit trophoblast infiltration and spiral artery remodeling through inhibition of cell migration, invasion, and tube formation mediated t...
Overall, these findings suggested that TARID may be a therapeutic target for PE through the CXCL3/ERK/MAPK pathway....
Several cancers, including lung adenocarcinoma (LUAD), are caused by genes related to necroptosis. However, it is still unknown how necroptosis-related long noncoding RNAs (lncRNAs) may be involved in...
The Cancer Genome Atlas (TCGA) database was used to download the LUAD transcriptome data and the associated clinical data. lncRNAs associated with necroptosis were screened using coexpression analysis...
The 14 lncRNAs in a novel NLPS were created. With further validation in the GSE30219 dataset, the risk score according to the NLPS was an independent prognostic indicator for LUAD patients. Patients w...
We constructed a novel NLPS that could predict OS and sensitivity to immunotherapy in LUAD patients....
Ferroptosis, a novel regulated cell death induced by iron-dependent lipid peroxidation, plays an important role in tumor development and drug resistance. Long noncoding RNAs (lncRNAs) are associated w...
Pancreatic cancer is a highly aggressive malignancy worldwide with rapid development and an exceedingly poor prognosis. lncRNAs play crucial roles in regulating the biological behaviors of tumor cells...
A series of loss- and gain-of-function experiments in vitro and in vivo were performed to explore the oncogenic role of LINC00578 in pancreatic cancer development and progression. Label-free proteomic...
LINC00578 positively regulated cell proliferation and invasion in vitro and tumorigenesis in vivo in pancreatic cancer. LINC00578 can obviously inhibit ferroptosis events, including cell proliferation...
This study elucidated that LINC00578 acts as an oncogene to promote pancreatic cancer cell progression and suppress ferroptosis by directly combining with UBE2K to inhibit the ubiquitination of SLC7A1...